abstract |
The present invention relates to the use of compounds of general formula (I) to reduce blood glucose and / or inhibit the secretion, circulation, or effect of insulin antagonist peptides such as CGRP or amylin. Accordingly, the compounds can be used in the treatment of NIDDM-related insulin resistance (non-insulin dependent diabetes mellitus) or aging. |